Intranasal immunization with tetanus toxoid and CNF1 as a new mucosal adjuvant protects BALB/c mice against lethal challenge.
Although often requiring the development of efficient adjuvants, needle-free mucosal delivery of vaccine is of major interest as a strategy of mass immunization against infectious diseases. We report that mucosal immunization against tetanus toxoid through nasal route, together with active cytotoxic necrotizing factor 1 (CNF1), elicits a specific and long lasting anti-tetanus toxin response, comprising seric IgG and IgA, as well as mucosal IgA. Immunized mice were protected against a challenge with lethal doses of tetanus toxin (10 x LD(50)). The Rho GTPase activating toxin CNF1 is thus an attractive mucosal adjuvant candidate for nasal vaccines.
Munro
Patrick
P
Institut National de la Santé et de la Recherche Médicale, INSERM, U627, Université de Nice-Sophia Antipolis, Faculté de Médecine, 28 Avenue de Valombrose, F-06107 Nice cedex 2, France. munro@unice.fr
Flatau
Gilles
G
Lemichez
Emmanuel
E
D000276:Adjuvants, Immunologic; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis / Q000097:blood; D001427:Bacterial Toxins / Q000276:immunology*; D029968:Escherichia coli Proteins / Q000276:immunology*; D005243:Feces / Q000737:chemistry; D005260:Female; D007070:Immunoglobulin A / Q000032:analysis / Q000097:blood; D007074:Immunoglobulin G / Q000032:analysis / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D009092:Mucous Membrane / Q000276:immunology; D017817:Nasal Lavage Fluid / Q000737:chemistry; D016019:Survival Analysis; D013742:Tetanus / Q000276:immunology / Q000517:prevention & control*; D013745:Tetanus Toxoid / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001427:Bacterial Toxins; D029968:Escherichia coli Proteins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D013745:Tetanus Toxoid; C060296:cytotoxic necrotizing factor type 1